A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Trial details
- Registry ID
- NCT06568692
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as eniluracil
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692 | Processa Pharmaceuticals | Phase 2 | Terminated | 2026-07-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |